RYLAZE FDA approval date
The FDA approved RYLAZE on 30 Jun 2021.
- FDA approval date
- 30 Jun 2021
- Source
- FDA record
Drug identity has not yet been verified against registry records
Also recorded as ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN
Included trials
No linked trials for this drug yet. Browse all trials
PDUFA dates and FDA decisions
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2021-06-30Day | RYLAZE | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761179", "applicant_as_listed_by_fda": "JAZZ PHARMS", "brand_names": ["RYLAZE"], "active_ingredients": ["ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210630", "matched_on": "drug record created from this FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |